

Sayem Osman

From: Ferenc, Christopher B. <christopher.ferenc@katten.com>
Sent: Monday, February 26, 2024 6:14 PM
To: Megan Raymond; J. Steven Baughman; Novo-Semaglutide-IPR@groombridgewu.com
Cc: Sodikoff, Brian
Subject: RE: IPR2024-00107
Attachments: 2024.02.26 - Stipulation Sun Invalidity Contentions.pdf

Some people who received this message don't often get email from christopher.ferenc@katten.com. [Learn why this is important](#)

Megan,

Please find attached the stipulation filed today in the underlying district court on behalf of Sun.

Regards,
Chris

Christopher B. Ferenc

Partner

Katten

Katten Muchin Rosenman LLP
1919 Pennsylvania Ave., NW., Suite 800 | Washington, DC 20006
direct +1.202.625.3647
christopher.ferenc@katten.com | katten.com

From: Megan Raymond <megan.raymond@groombridgewu.com>
Sent: Wednesday, November 22, 2023 12:12 AM
To: Ferenc, Christopher B. <christopher.ferenc@katten.com>; J. Steven Baughman <steve.baughman@groombridgewu.com>; Novo-Semaglutide-IPR@groombridgewu.com
Cc: Sodikoff, Brian <brian.sodikoff@katten.com>
Subject: RE: IPR2024-00107

EXTERNAL EMAIL – EXERCISE CAUTION

Christopher,

Attached is the proposed joint stipulation. When you have a chance, please let us know if we may proceed with filing it. We'll plan to file it at some point next week.

Sincerely,
Megan

From: Ferenc, Christopher B. <christopher.ferenc@katten.com>
Sent: Monday, November 20, 2023 3:16 PM
To: Megan Raymond <megan.raymond@groombridgewu.com>; J. Steven Baughman <steve.baughman@groombridgewu.com>; Novo-Semaglutide-IPR@groombridgewu.com
Cc: Sodikoff, Brian <brian.sodikoff@katten.com>
Subject: RE: IPR2024-00107

You don't often get email from christopher.ferenc@katten.com. [Learn why this is important](#)

Megan,

Sun is fine with the draft.

Regards,
Chris

Christopher B. Ferenc
Partner

Katten

Katten Muchin Rosenman LLP
1919 Pennsylvania Ave NW - Suite 800 | Washington, DC 20006-3404
direct +1.202.625.3647
christopher.ferenc@katten.com | katten.com

From: Megan Raymond <megan.raymond@groombridgewu.com>
Sent: Monday, November 20, 2023 1:17 PM
To: Ferenc, Christopher B. <christopher.ferenc@katten.com>; J. Steven Baughman <steve.baughman@groombridgewu.com>; Novo-Semaglutide-IPR@groombridgewu.com
Cc: Sodikoff, Brian <brian.sodikoff@katten.com>
Subject: RE: IPR2024-00107

EXTERNAL EMAIL – EXERCISE CAUTION

Chris,

This is generally ok with us, though we will need permission from the PTAB to file a stipulation in lieu of Novo filing an opposition to the motion for joinder. A draft email to the Board is below. Please let us know your thoughts.

The parties respectfully request a call with the Board seeking permission to file a stipulation addressing Sun's motion for joinder in lieu of Patent Owner Novo filing an opposition (due December 4), as the Board authorized in related IPR2024-00009. The parties are available tomorrow at 9-10am, 11am-2pm, or 4pm-5pm or as the Board otherwise directs.

Sincerely,
Megan

From: Ferenc, Christopher B. <christopher.ferenc@katten.com>
Sent: Monday, November 20, 2023 12:01 PM
To: J. Steven Baughman <steve.baughman@groombridgewu.com>; Megan Raymond <megan.raymond@groombridgewu.com>; Novo-Semaglutide-IPR@groombridgewu.com
Cc: Sodikoff, Brian <brian.sodikoff@katten.com>
Subject: IPR2024-00107

You don't often get email from christopher.ferenc@katten.com. [Learn why this is important](#)

Counsel,

We are writing on behalf of Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (together "Sun") regarding the Motion for Joinder filed in IPR2024-00107 (the "Motion").

We understand that Novo and Dr. Reddy's intend to file a stipulation today regarding a similar motion filed in IPR2024-00009. Sun is willing to enter into the same stipulation. Please confirm that works on your end. We are available to discuss this afternoon or tomorrow morning.

Best,

Chris Ferenc
Counsel for Sun

Christopher B. Ferenc
Partner

Katten

Katten Muchin Rosenman LLP
1919 Pennsylvania Ave NW - Suite 800 | Washington, DC 20006-3404
direct +1.202.625.3647
christopher.ferenc@katten.com | katten.com

=====

CONFIDENTIALITY NOTICE:

This electronic mail message and any attached files contain information intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any viewing, copying, disclosure or distribution of this information may be subject to legal restriction or sanction. Please notify the sender, by electronic mail or telephone, of any unintended recipients and delete the original message without making any copies.

=====

NOTIFICATION: Katten Muchin Rosenman LLP is an Illinois limited liability partnership that has elected to be governed by the Illinois Uniform Partnership Act (1997).

=====

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any

review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.